# Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease

> **NCT03980938** · PHASE2 · TERMINATED · sponsor: **EIP Pharma Inc** · enrollment: 15 (actual)

## Conditions studied

- Huntington Disease

## Interventions

- **DRUG:** neflamapimod
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03980938
- **Lead sponsor:** EIP Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-07-08
- **Primary completion:** 2020-10-15
- **Final completion:** 2020-10-15
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Due to the long delay because of COVID-19 and results from another study suggesting a higher dose may be more beneficial, EIP Pharma decided on October 15th, 2020, to end the trial prematurely.
- **Last updated:** 2022-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03980938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03980938, "Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03980938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*